Skip to main content
. Author manuscript; available in PMC: 2013 Jan 1.
Published in final edited form as: Cancer Nurs. 2012 Jan;35(1):E18–E26. doi: 10.1097/NCC.0b013e31821404c0

Table 3.

Disease and Treatment Data

Characteristic Number (%) (n=39)
Breast cancer-related data
 Location
  left 23 (59.0)
  right 13 (33.3)
  bilateral 3 (7.7)
 Stage at diagnosis
  I 9 (23.1)
  II 21 (53.8)
  III 8 (20.5)
  IV 1 (2.6)
 Surgery type
  Lumpectomy/Segmental 17 (43.6)
  Modified radical mastectomy 16 (41.0)
  Radical mastectomy 3 (7.7)
  Other 3 (7.7)
 Chemotherapy type
  Cytoxan Adriamycin 5Fu 3 (7.7)
  Adriamycin Cytoxan 10 (25.6)
  Cytoxin Methatrexate 5fu 4 (10.3)
  Other/Missing/None 22 (56.4)
 Radiation
  None 11 (28.2)
  Some 28 (71.8)
 Complete treatment received
  Surgery alone 2 (5.1)
  Surgery and radiation 1 (2.6)
  Surgery and chemotherapy 9 (23.1)
  Surgery, radiation, and chemotherapy 27 (69.2)
 Time since breast cancer diagnosis, Mean ± SD (years) 8.57±6.74

Lymphedema Data
 Location
  Left arm 23 (59.0)
  Right arm 16 (41.0)
 Lymphedema dominant arm 18 (46.2)
 BMI Group
  <30 19 (48.7)
  ≥30 20 (51.3)
 Lymphedema duration, Mean ± SD (years) 5.75±4.06
 Lymphedema onset since breast cancer diagnosis, Mean ± SD (years) 2.74±5.65